- Home
- TBLD vs SLS Comparison
TBLD vs SLS Comparison
Compare TBLD & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TBLD | SLS |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 702.5M | 706.7M |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | TBLD | SLS |
|---|---|---|
| Price | $21.77 | $5.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 74.1K | ★ 4.1M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 5.80% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $110.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.00 | $1.39 |
| 52 Week High | $23.02 | $6.14 |
Technical Indicators
Market Signals| Indicator | TBLD | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 49.16 | 54.63 |
| Support Level | $19.57 | $4.70 |
| Resistance Level | $22.93 | $5.28 |
| Average True Range (ATR) | 0.58 | 0.28 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 27.85 | 67.34 |
Price Performance
Historical ComparisonAbout TBLD Thornburg Income Builder Opportunities Trust
Thornburg Income Builder Opportunities Trust is a diversified, closed-end management investment company. The Trust's investment objective is to provide current income. The Trust will seek to achieve its investment objective by investing, directly or indirectly, at least 80% of its Managed Assets.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.